GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations

Acute myeloid leukemia (AML) is a heterogeneous disease with variable treatment outcome. Despite recent advances in understanding the key molecular mechanisms of myeloid leukemogenesis, risk stratification remains imperfect, particularly in the intermediate risk group in which a large proportion of patients have a normal karyotype.